Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LY4170156 · 1 trial · 7 indications
Number of participants with dose-limiting toxicities (DLTs)
Number of participants with DLTs
Number of participants with DLTs
Number of participants with DLTs
ORR per investigator assessed Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1)
ORR per RECIST 1.1
A summary of SAEs regardless of causality, will be reported in the Reported Adverse Events module
| Arm | Type | Description |
|---|---|---|
| Sofe-M (Dose-escalation, Cohort A1) | EXPERIMENTAL | Escalating doses of Sofe-M administered intravenously (IV) |
| Sofe-M (Cohort A1 Parts A and C) | EXPERIMENTAL | Sofe-M administered IV |
| Sofe-M Alone or with Itraconazole. Drug-Drug Interaction (DDI) (Cohort A1: Arm B) | EXPERIMENTAL | Sofe-M administered IV and itraconazole administered orally |
| Sofe-M (Dose-optimization, Cohort A2) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV |
| Sofe-M (Enrichment Cohort A3) | EXPERIMENTAL | Monotherapy administered IV |
| Sofe-M (Combination Cohort A4) | EXPERIMENTAL | Combination with bevacizumab administered IV |
| Sofe-M (Combination Cohort A5) | EXPERIMENTAL | Combination with carboplatin administered IV |
| Sofe-M Combination with Pembrolizumab (Dose-optimization Cohort A6) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with pembrolizumab |
| Sofe-M Combination with carboplatin and optional bevacizumab (Dose-optimization Cohort A7) | EXPERIMENTAL | Comparing 2 or more doses (evaluated during dose escalation) of Sofe-M administered IV with or without bevacizumab |
| Sofe-M (Dose-expansion, Cohort B2-B4) | EXPERIMENTAL | Sofe-M administered IV |
| Sofe-M (Dose-expansion, Cohort B1) | EXPERIMENTAL | Sofe-M administered IV |
| Name | Type | Description |
|---|---|---|
| Sofe-M | DRUG | Intravenous |
| bevacizumab | DRUG | IV |
| carboplatin | DRUG | IV |
| Itraconazole | DRUG | oral |
| pembrolizumab | DRUG | IV |
Inclusion Criteria: * Have one of the following solid tumor cancers: * Dose Escalation: Ovarian (epithelial ovarian, primary peritoneal, and fallopian tube) cancer, endometrial cancer, cervical cancer, non-small cell lung cancer (NSCLC), triple negative breast cancer (TNBC), pancreatic cancer, o...
LY4170156 is an investigational small molecule being developed for the treatment of ovarian neoplasms. It is also being studied in other advanced solid tumors, including endometrial, cervical, non-small-cell lung, triple negative breast, pancreatic, and colorectal cancers, according to the ongoing clinical trial.
LY4170156 targets the folate receptor alpha (FRα), a protein that is often overexpressed in certain cancers. By targeting FRα, the drug is designed to interfere with cancer cell growth and survival. This mechanism is being evaluated in a Phase 1 clinical trial for advanced solid tumors.
LY4170156 is being developed by Eli Lilly and Company, a pharmaceutical company listed on the New York Stock Exchange under the ticker symbol LLY. The company is currently conducting a Phase 1 clinical trial to evaluate the drug's safety and efficacy in patients with selected advanced solid tumors.
LY4170156 is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting participants to study the drug in advanced solid tumors, including ovarian cancer.
LY4170156 is being studied in a Phase 1 clinical trial with the identifier NCT06400472. This trial is titled 'A Study of LY4170156 in Participants With Selected Advanced Solid Tumors' and is currently recruiting participants. The trial is expected to enroll approximately 495 participants across multiple countries.
LY4170156 is a unique investigational drug developed by Eli Lilly and Company. No alternative names for this drug have been disclosed. It is a small molecule that targets the folate receptor alpha (FRα) and is being studied for the treatment of ovarian neoplasms and other advanced solid tumors.